42 results
Otsuka America Pharmaceutical, Inc
Usage: ABILIFY ASIMTUFII is indicated for the treatment of schizophrenia in adults and for the maintenance monotherapy treatment of bipolar I disorder in adults.
Otsuka America Pharmaceutical, Inc.
Usage: ABILIFY MAINTENA (aripiprazole) is indicated for the treatment of schizophrenia in adults and for the maintenance monotherapy treatment of bipolar I disorder in adults.
REMEDYREPACK INC.
Usage: Aripiprazole oral tablets are indicated for the treatment of schizophrenia and Tourette’s disorder.
American Health Packaging
Usage: Aripiprazole oral tablets are indicated for the treatment of schizophrenia and Tourette’s disorder.
SQUARE PHARMACEUTICALS LIMITED
Greenstone LLC
Usage: Asenapine sublingual tablets are indicated for the treatment of schizophrenia in adults and bipolar I disorder, including acute manic or mixed episodes in patients aged 10 to 17. It is also used as adjunctive treatment with lithium or valproate and for maintenance monotherapy in adults.
Alembic Pharmaceuticals Limited
Usage: Asenapine is indicated for Bipolar I disorder, including acute monotherapy of manic or mixed episodes in pediatric patients aged 10 to 17 years, and as adjunctive treatment with lithium or valproate in adults.
Intra-Cellular Therapies, Inc
Usage: CAPLYTA is indicated for the treatment of schizophrenia in adults and for depressive episodes associated with bipolar I or II disorder in adults, used both as monotherapy and adjunctively with lithium or valproate.
Aurobindo Pharma Limited
Usage: Clozapine orally disintegrating tablets are indicated for treatment-resistant schizophrenia in patients who haven't responded to standard antipsychotics, and for reducing the risk of recurrent suicidal behavior in schizophrenia or schizoaffective disorder patients at chronic risk.
Mayne Pharma Commercial LLC
Usage: Clozapine tablets are indicated for treatment-resistant schizophrenia in patients unresponsive to standard antipsychotics and for reducing the risk of recurrent suicidal behavior in those with schizophrenia or schizoaffective disorder at chronic risk. Its effectiveness has been demonstrated in clinical studies.
OSZAR »